Phase 3 Clinical Trials With Primary Completion Dates in October 2021

This is a list of Phase 3 trials with primary completion dates in October 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
CBDYTarget Group Inc.2021-10-01Phase 3NCT04241315ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
CDTXCidara Therapeutics, Inc.2021-10-01Phase 3NCT03667690Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
MIRMMirum Pharmaceuticals, Inc.2021-10-01Phase 3NCT03905330A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
NEPHNephros, Inc.2021-10-01Phase 3NCT04765371Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, With CoViD-19
RIGLRigel Pharmaceuticals, Inc.2021-10-01Phase 3NCT03764618A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
STSASatsuma Pharmaceuticals, Inc.2021-10-01Phase 3NCT04406649A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
SYGGFSynairgen plc2021-10-01Phase 3NCT04732949Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19
TNXPTonix Pharmaceuticals Holding Corp.2021-10-01Phase 3NCT04508621A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia